Regulatory Expertise
Deep knowledge of FDA, international, and emerging regulatory requirements, embedded in every aspect of our operations.
EXPERTISE
Pharmaceutical packaging exists within one of the most heavily regulated environments in any industry. Every label, every carton, every serialized unit must meet exacting regulatory requirements that span federal, state, and international jurisdictions. Meridan has built a regulatory affairs capability that goes well beyond basic compliance. Our quality and regulatory teams bring decades of combined experience in navigating complex regulatory landscapes, anticipating emerging requirements, and ensuring that our customers' products are packaged and labeled in full compliance with all applicable standards.
ALWAYS READY
FDA Inspection Readiness
Meridan operates in a continuous state of FDA inspection readiness. This is not a posture adopted in response to a pending inspection notification. It is a daily operational discipline embedded in every facility and every function. Our philosophy is that if an FDA investigator walked through the door at any moment on any given day, our facilities, documentation, and personnel would be ready for scrutiny.
This readiness is maintained through several key practices. Each facility conducts quarterly mock FDA inspections using structured audit protocols that mirror the FDA's current inspection approach. These mock inspections are led by experienced quality professionals who have direct exposure to FDA regulatory expectations and common inspection focus areas. Findings from mock inspections are treated with the same rigor as actual regulatory observations, with formal corrective actions documented and tracked through the CAPA system.
Meridan maintains rapid response protocols that activate immediately upon notification of a regulatory inspection. Front room and back room teams are pre-designated at each facility, with defined roles and responsibilities for managing inspector interactions, document retrieval, subject matter expert coordination, and real-time communication with corporate quality leadership. These protocols are rehearsed regularly to ensure smooth execution under the pressure of an actual inspection.
Readiness Program Elements
- Quarterly mock FDA inspections at each facility
- Pre-designated front room and back room teams
- Rapid document retrieval protocols
- Subject matter expert availability matrices
- Real-time corporate quality communication
- Post-inspection response management
- Annual inspection trend analysis and training updates
GLOBAL REACH
International Regulatory Knowledge
While Meridan's facilities are based in the United States, many of our customers distribute products globally. This requires packaging and labeling operations that comply not only with FDA requirements but also with the regulatory frameworks of international markets. Meridan's regulatory team maintains working knowledge of key international standards, including European Union GMP requirements as defined in EudraLex Volume 4 and its associated Annexes, Health Canada's Food and Drug Regulations and GUI-0001 guidelines, and the harmonized guidance documents published by the International Council for Harmonisation (ICH).
This international expertise is particularly critical for labeling operations, where text, symbols, language requirements, and regulatory reference numbers vary by market. Meridan's labeling capabilities include multi-language label production, country-specific regulatory symbol placement, and market-specific serialization and tamper-evidence requirements. Our quality team works directly with customers' regulatory affairs departments to ensure that labeling artwork and content meet the requirements of every intended market.
Meridan also monitors international regulatory developments through participation in industry associations, regulatory intelligence services, and direct engagement with standards-setting bodies. This proactive approach ensures that Meridan is prepared for emerging requirements before they take effect, reducing the compliance burden on our customers during regulatory transitions.
SERIALIZATION
DSCSA Compliance
The Drug Supply Chain Security Act (DSCSA) represents one of the most significant regulatory developments affecting pharmaceutical packaging operations in the past decade. DSCSA requires unit-level serialization, verification, and tracing of prescription pharmaceutical products throughout the United States supply chain. As a contract packager, Meridan plays a critical role in ensuring that serialized product data is accurately applied, captured, and transmitted to customers and downstream trading partners.
Meridan has invested heavily in serialization infrastructure across all three facilities. Each packaging line equipped for serialized products features integrated vision inspection systems that verify the accuracy and readability of serialized data at the unit, bundle, case, and pallet levels. Aggregation relationships are established and maintained through the packaging process, ensuring that the hierarchical parent-child relationships between serialized identifiers are accurately recorded and reported.
Meridan's serialization systems support all major Electronic Product Code Information Services (EPCIS) event types, enabling seamless data exchange with customers' enterprise serialization platforms and compliance with the interoperable, electronic tracing requirements established by the FDA. Our systems generate and transmit commissioning, packing, and shipping events in standardized formats compatible with the leading serialization and track-and-trace platforms used by pharmaceutical manufacturers and distributors.
Verification capabilities include both product identifier verification and suspect product investigation protocols. Meridan maintains documented procedures for responding to verification requests from authorized trading partners and for investigating and reporting suspect or illegitimate products in accordance with FDA requirements and DSCSA timelines.
DATA GOVERNANCE
Data Integrity
Data integrity is a foundational element of Meridan's quality management system and a top priority in the current regulatory environment. The FDA, EMA, and other global regulatory agencies have significantly increased their focus on data integrity during inspections, making it essential that contract packaging operations can demonstrate the reliability and trustworthiness of all data generated during production activities.
Meridan's data integrity program is built on the ALCOA+ principles: data must be Attributable, Legible, Contemporaneous, Original, and Accurate, plus Complete, Consistent, Enduring, and Available. These principles are applied across all data types generated during packaging operations, including electronic batch records, equipment logs, environmental monitoring data, laboratory results, and quality system records.
All electronic systems that generate, process, or store GMP-regulated data comply with 21 CFR Part 11 requirements for electronic records and electronic signatures. This includes validated user access controls with unique user identifications, electronic audit trails that capture all data entries, modifications, and deletions with timestamps and user attribution, and system validation documentation that demonstrates the fitness of each system for its intended purpose. Meridan also aligns with EU Annex 11 guidance on computerized systems, ensuring that data generated at our facilities meets the expectations of both US and international regulators.
SAFETY
Pharmacovigilance and Complaint Handling
Meridan operates a robust product complaint investigation system that serves as a critical link in the broader pharmacovigilance chain. When a product complaint is received that relates to packaging, labeling, or the physical integrity of a packaged product, Meridan's quality team initiates a structured investigation that includes review of relevant batch records, examination of retained samples, assessment of in-process inspection data, and evaluation of potential root causes within the packaging operation.
Investigation findings are documented in detailed reports that provide customers with the information they need to complete their own complaint assessments and, where applicable, support regulatory reporting obligations. Meridan's complaint investigation timelines are aligned with FDA requirements for timely evaluation and with customers' internal pharmacovigilance reporting deadlines.
For complaints that involve potential adverse events or safety signals, Meridan provides rapid escalation and preliminary assessment support to help customers meet their adverse event reporting timelines under 21 CFR Part 314.81 and other applicable regulations. While adverse event reporting responsibility rests with the marketing authorization holder, Meridan recognizes its role as a critical source of packaging-related investigation data and prioritizes responsiveness and thoroughness in every complaint investigation.
Across our combined operations, Meridan's facilities have successfully hosted more than 50 FDA and international regulatory inspections with a consistent track record of compliance excellence.
Our regulatory experience spans pre-approval inspections, routine surveillance inspections, for-cause investigations, and international regulatory authority visits. This depth of inspection experience has built institutional knowledge that benefits every customer we serve.
Ready to optimize your packaging operations?
Partner with Meridan for reliable, compliant pharmaceutical packaging at scale.